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Abstract  
It has been known since the early 1970s that nuclear receptor complexes bind DNA in 
association with co-regulatory proteins. Characterization of these nuclear receptor coregulators 
has revealed diverse enzymatic activities which temporally and spatially coordinate nuclear 
receptor activity within the context of local chromatin in response to diverse hormone signals. 
Chromatin modifying proteins, which dictate the higher order chromatin structure in which DNA 
is packaged, in turn orchestrate orderly recruitment of nuclear receptor complexes. Modifications 
of histones include acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ADP 
ribosylation, deimination and proline isomerization (1). At this time, we understand how a subset 
of these modifications regulates nuclear receptor signaling. However the effects, particularly of 
acetylation and demethylation, are profound. The finding that nuclear receptors are directly 
acetylated and that acetylation in turn directly regulates contact-independent growth has broad 
therapeutic implications. Studies over the past 7 years have led to the understanding that nuclear 
receptor acetylation is a conserved function, regulating diverse nuclear receptor activity. 
Furthermore we now know that acetylation of multiple and distinct substrates within nuclear 
receptor signaling pathways, form an acetylation signaling network from the cell surface to the 
nucleus. The finding that NAD-dependent histone deacetylases, the sirtuins, are capable of 
deacetylating nuclear receptors provides a new level of complexity in the control of nuclear 
receptor activity in which local intracellular concentrations of NAD may regulate nuclear 
receptor physiology.  
 
 
 
 
 Nuclear Receptors Co-regulator Enzyme Complexes  
In the early 1970s initial attempts at purifying nuclear receptors were confounded by the large 
number of co-associated proteins. The O’Malley laboratory had characterized the nuclear 
progesterone receptor/DNA complex and the thyroid hormone receptor associated with a 
heterogenous group of proteins that was regulated in a ligand-dependent manner (2, 3). It was 
apparent that transcription factors contained transactivation domains which functioned as 
modular surfaces to regulate transcription independently of direct binding to DNA (4). The 
laboratory of Tjian and others characterized the TATA box binding protein-associated factors 
termed TAFs (5). Several cell-type specific activities were characterized and shown to regulate 
transcription factor activity. In this regard a B cell-specific activity designated Oct coactivator 
from B cells (OCA-B) regulated Oct-dependent B cell specific transcription (6).   
Cross squelching experiments by the Chambon laboratory (7) suggested distinct classes of 
transcriptional activation domains existed within nuclear receptors. Consistent with the notion 
that nuclear receptors were capable of repressing transcription, formal evidence that nuclear 
receptors contain specific repression domains was provided by studies of the progesterone 
receptor and retinoic acid receptor (8, 9). These studies provided the rational basis for the 
identification of proteins mediating transcriptional activation and repression of nuclear receptors. 
Yamamoto identified the SWI protein as a key activator of the glucocorticoid receptor in yeast 
(10). In 1994, CBP was cloned as a coactivator of CREB (11) and p300 as an E1A-interacting 
protein (12, 13). Of fundamental importance was the identification of histone acetyltransferase 
enzymatic activity within the p300 activation domain. These proteins were shown to function as 
rate-limiting co-activators of nuclear receptor activity partially dependent upon their intrinsic 
histone acetyltransferase activity.  
A dynamic and rapidly evolving field has characterized diverse types of enzymes (14). 
Furthermore, the assembly of these enzymes was shown to be temporally coordinated. The 
histone acetyltransferase, p300, enhanced the efficiency of transcriptional initiation from an 
estrogen-regulated template assembled within chromatin. The reassembly of active complexes 
during subsequent rounds of reinitiation did not require p300 (14). Indeed consistent with these 
findings, chromatin immunoprecipitation experiments identified temporarily coordinated multi-
protein complexes associated with ERα and with endogenous ERα DNA binding sites. These 
studies showed coactivators were recruited in a cyclical manner in association with local 
chromatin. p300 was recruited to the promoter region of the ERα-responsive genes in the first 
phase of ERα binding, but not in subsequent cycles of ERα recruitment (15).  
Nuclear receptor acetylation governs cellular growth potential  
Histone acetyltransferases have been shown to acetylate diverse substrates. The first evidence 
that nuclear receptors served as direct substrates for histone acetyltransferases were studies by Fu 
et al. (16). The residues of AR acetylated by p300 in vitro were conserved between species. Point 
substitution mutations of the acetylation sites identified in vitro regulated ligand-dependent 
transactivation. Subsequent studies demonstrated that the nuclear receptor acetylation site is 
conserved between a subset of nuclear receptors, including the ERα, TRβ (17), PR and the GR 
(18). With each of the nuclear receptors characterized to date, the acetylation sites regulate a 
subset of nuclear receptor functions with the AR currently being the best characterized. The 
addition of ligand, dihydrotestosterone, or other agonists such as bombesin, enhances androgen 
receptor acetylation (19). When reintroduced into AR-deficient human prostate cancer cells, gain 
of function point substitution of the AR acetylation site resulted in receptors that promote 
prostate tumor growth, both in vitro and in vivo (20). Characterization of the mechanism by 
which the androgen receptor acetylation site regulated contact-independent growth, indicated 
both enhancement of cellular proliferation and a reduction in cellular apoptosis (20, 21). The 
charge of lysine residues in the AR acetylation site regulated recruitment of p300, and in a 
reciprocal manner, disengagement of corepressor complexes including NCoR, HDAC, and Smad 
3 (20).  
The AR acetylation site regulates prostate cellular apoptosis. The Jun kinase kinase 
signaling pathway (MEKK1) induces cellular apoptosis in the presence of the AR. The AR 
acetylation site governs TRAIL-induced cellular apoptosis (21). Cells transduced with AR 
acetylation site gain-of-function mutants enhanced proliferation, associated with the induction of 
cell cycle markers such as Ki67 and cyclin D1. The relative abundance of cyclin D1 was 
increased in cells transduced with the AR activating mutants.  
Chromatin immunoprecipitation analysis demonstrated that in addition to the enhanced 
recruitment of the AR to an androgen-responsive element binding site (ARE), the histone 
deacetylase inhibitor, TSA, enhanced AR recruitment in an AR acetylation site-dependent 
manner (22). AR acetylation site dead mutants showed reduced recruitment to the PSA promoter 
androgen-responsive element and reduced TSA-dependent recruitment. This suggests that the 
acetylation site of the nuclear receptor regulated access in the context of local chromatin (22).   
 
 The ERα was shown to be acetylated at the same motif as the AR (23). Deletion 
analysis identified the primary site acetylated by p300 and a minimal peptide sufficient to serve 
as a substrate for p300 was characterized. The peptide encoding the ERα acetylation site 
conveyed similar substate specificity as histone H3. Proteomic analysis including LC/MS and 
Edman degradation sequencing, demonstrated K302 and K303 were preferential sites of 
acetylation. Lys K303 is frequently mutated in human breast cancer (24). The ERα acetylation 
mutants function as hyperactive mutants in the presence of low concentrations on its ligand 
estradiol (23, 24). The ERα coactivator SRC1 is acetylated, and point mutation of the SRC1 
acetylation site results in an ACTR hyperactive mutant that fails to be transcriptionally down 
regulated (25). As mutation of the ERα and the ERα coactivator ACTR acetylation site, 
enhances ligand-dependent acetylation may serve to repress hormone signaling by recruiting co-
repressor activity as shown for PGC1α (26), or through docking others as-yet-to-be-defined 
complexes. Consistent with this model ERα repression by BRCA1 (27, 28) is abolished by 
mutation of the ERα K302/303 acetylation site (RGP. CW unpublished data). Like PGC1α and 
p53, in which multiple acetylation sites have been identified (29), ERα has recently been shown 
to be acetylated at the additional residue K266/K268 (30). In these studies, SRC1/p300 was used 
as the source of HAT. The relative importance of the K302/303 vs. the K266/K268 site in the 
diverse physiological roles of the ERα remains to be determined.   
 
A body of evidence has contributed to the current understanding that PGC1α, a 
transcriptional co-activator of nuclear receptors, is acetylated and the acetylation of PGC1α 
regulates cellular metabolism. The metabolic coactivator PGC1α modulates the gluconeogenic 
pathway in fasting and diabetic states through interaction with several transcription factors (31, 
32). PGC1α forms part of a multi-protein complex that includes the TRAP/Mediator complex, 
including TRAP220 binding to its C-Terminus (33). The endogenous PGC1α complex includes 
the histone acetyltransferase GCN5. p300 and SRC1 bind the N-terminal activation domain of 
PGC1α (34). PGC1α is directly acetylated by GCN5 resulting in a transcriptionally inactive 
protein which relocalizes from promoter regions to nuclear foci (26).  
Acetylation of components within hormone signaling pathways  
The addition of liganded nuclear receptor to a cell induces multiple downstream signaling 
cascades. A growing body of evidence has demonstrated that several additional components 
which regulate nuclear receptor signaling pathways are themselves substrates for histone 
acetyltransferases (Fig. 1). Additional components of nuclear receptor signaling cascade that are 
directly acetylated include MEKK1, Hsp90 (35, 36), and IKK (37). The acetylation of these 
nuclear receptor binding proteins, in turn, affects nuclear receptor function. Thus, for example, 
Hsp90-mediated glucocortical receptor (GR) maturation is regulated by acetylation of Hsp90 
(36). Within the nucleus, components of the nuclear receptor coactivator or corepressor 
complexes are themselves substrates for histone acetyltransferases. Thus ACTR and MTA1 are 
histone acetylases, and ACTR and PGC-1α serve as substrates for histone acetyltransferases (25, 
26). Other transcription factors known to work in trans to regulate nuclear receptor signaling, 
such as the forked protein, are acetylated, providing an additional level of complexity for cross 
talk between (FKHR) and ERα signaling (38).  
The NAD-dependent histone deacetylases regulate hormone signaling  
The histone deacetylases are divided into three groups. The Class 1 and 2 HDACs share 
homology to the yeast Rpd3p and Hda1p proteins. The Class 3 HDACs are homologus to the 
yeast transcriptional repressor Sir2p. The Class 3 HDACs are nicotinamide adenine dinucleotide 
(NAD)-dependent. Mammalian Sirtuins are conserved with 7 genes homologous to the yeast Sir2 
gene. The nuclear sirtuins (SIRT1, SIRT6 and SIRT7), the mitochondrial sirtuin (SIRT3, SIRT4 
and SIRT5) and cytosolic (SIRT2) regulate diverse metabolic function. The distinct substrates 
and subcellular localization of the mammalian Sirtuins suggests significant diversity of function 
(39, 40).   
 
SIRT1 has been characterized in its interactions with nuclear receptors and nuclear 
receptor coactivators. The functional interactions between SIRT1 and nuclear receptor signaling 
has been examined for the cointegrators p300 (41) and PGC1α (42-44), and for the nuclear 
receptor AR (45), PPARγ (46) and ERα (47). SIRT1 has been shown to deacetylate coactivators 
PGC1α and p300 and the nuclear receptors ERα and AR. SIRT1 regulates repression of the co-
activator p300, providing a mechanism by which the NAD-dependent HAT deacetylases may 
regulate diverse nuclear receptor functions (41). The p300 coactivator functions as a rate-limiting 
protein in regulating diverse nuclear receptor functions. A direct link between the NAD-
dependent histone deacetylases and the histone acetyltransferases was first demonstrated by 
Bouras et al  (36) (Fig. 1). SIRT1 repressed p300 in an NAD-dependent manner. The lysine 
residues within the Cell Cycle Regulatory Domain (CRD1) of p300 were essential for SIRT1-
mediated repression. Importantly Bouras et al demonstrated that lysine residues within p300 
function as substrates for SIRT2 (41). SIRT1 also functions as a substrate for sumoylation (41). 
SSP3, a sumo specific protease, antagonized SIRT1-mediated repression of p300. Importantly 
these studies suggest a link between local metabolic changes which are anticipated to alter the 
NAD/NADH ratio and p300 activity. As sirtuins are regulated by NAD, endogenous levels of 
nicotinamide may limit SIRT1 function and thereby alter activity of many transcription factors 
and nuclear receptors which are regulated by p300.   
 
Sirtuins have well characterized functions in regulating responses to caloric restriction 
and glucose metabolism, cellular growth and DNA repair. SIRT1 regulates gluconeogenesis by 
promoting the repression of glycolytic gene function (40). Importantly, recent studies have 
linked SIRT1-dependent deacetylation of the nuclear receptor coactivator PGC1α to glucose 
homeostasis. PGC1α is acetylated in vivo (43).  Acetylation of PGC1α was augmented by 
treatment with the SIRT1 inhibitor nicotinamide or by expression of the transcriptional 
coactivator p300 (28). The finding that SIRT1 associates with PGC1α (28) led to studies 
examining the biological significance of PGC1α acetylation. Fasting was shown to induce 
PGC1α deacetylation in skeletal muscle. This important study, identifying SIRT1 as a functional 
regulator of PGC1α to induce mitochondrial fatty acid oxidation in vivo, has broad implications 
for the understanding of adaptations to altered availability of nutrients. SIRT1 is increased in the 
fasted liver, thereby deacetylating and activating PGC1α, enhancing hepatic glucose output (43).    
 
These studies imply that PGC1α abundance may in turn govern metabolic diseases such 
as obesity and diabetes. Recent studies using Resveratrol (RSV), a known activator of SIRT1 
(48), demonstrated an increased aerobic capacity and induction of oxidative phosphorylation and 
mitochondrial biogenesis, primarily mediated by RSV-mediated inhibition of PGC1α acetylation 
and an increase in PGC1α activity (49). Resveratrol was also shown to oppose the effects of a 
high calorie diet producing chances associated with longer lifespan (50). Caloric restruction 
enhances SIRT1 binding to and repression of PPARγ-responsive gene promoters. SIRT1 
repressed PPARγ activity through binding the co-repressors NCoR and SMRT (46). Consistent 
with the physiological significance of SIRT1-mediated repression of PPARγ activity, SIRT1
+/-
mice demonstrated defective mobilization of fatty acids from white adipocytes upon fasting (46). 
Whether PPARγ or components within a PPARγ complex are direct substrates of acetylation, 
remains to be determined. Collectively, these studies demonstrate the important physiological 
role for PGC1α acetylation and a key role for the NAD-dependent histone deacetylase SIRT1 in 
regulating fat metabolism.   
 
Recent studies have provided indirect evidence for an additional potential functional 
interaction between nuclear receptors and the sirtuins. Studies from the laboratories of Rosenfeld 
and Glass demonstrated the induction of transient double-stranded DNA breaks upon the 
addition of estradiol, and the recruitment of ERα, PARP-1 and DNA topoisomerase IIβ (51). The 
BRCA1 gene which plays an essential role in DNA repair, is known to bind the ERα in the 
context of local chromatin in a temporally coordinated manner (28). Although the role of ERα 
acetylation in recruitment to double-stranded DNA breaks is unknown, Sirtuins, in particular 
SIRT6, regulate DS-DNA break repair. SIRT6 plays a key role in resistance to DNA damage and 
suppression of genomic instability (52). The fibroblasts of SIRT1
-/-
mice showed enhanced 
sensitivity to DNA damaging agents. Although the sirtuins and the ERα have both been 
independently implicated in DS-DNA break repair, it remains to be determined with sirtuins 
regulate this nuclear receptor function.  
The use of Sirt1 inhibitors has strongly implicated endogenous SIRT1 in regulating AR 
activity in prostate cancer cells (37). SIRT1 colocalizes with the AR in nuclear subdomains (37). 
SIRT1 inhibits cellular proliferation in an AR-dependent manner. SIRT1 antagonists induce 
endogenous AR expression and enhance DHT-mediated AR-dependent gene expression. SIRT1 
physically binds to and deacetylates the AR at a conserved lysine motif. The AR served as a 
substrate for the SIRT1 orthologs of several species including the mouse mSir2a, hSirt1 and two 
other enzymes Cerevisiae (SIR2p) and Archaeoglobus fulgidus (Sir2af2). Each of these enzymes 
were examined for deacetylation activity against a synthetic AR peptide known to be acetylated 
by p300. The deacetylation of the AR by the Sirtuins of several species was characterized by 
LCMS and MSMS fragmentation analysis. Thus the AR is a deacetylated by SIRT1 to inhibit 
ligand-dependent AR activity to thereby inhibit DHT-dependent prostate cancer cellular 
proliferation.   
What might be the physiological role of Sirtuin dependent regulation of nuclear receptor 
function? Sirtuin expression and activity is itself under complex control and may impact nuclear 
receptor function. The importance of NAD in Sir2 activity implies Sir2 activity may be regulated 
by intracellular NAD, by the NAD/NADH ratio, or nicotinamide (53, 54). Elevated lactate, 
which reduces the NAD/NADH ratio, is predicted to inhibit SIRT1 (55).  Inhibition of SIRT1 
may enhance AR function (45) with consequent anabolic repair effects within muscle (56, 57). 
During prostate cancer progression a shift towards cytosolic glycolysis occurs (58, 59). Increased 
local lactate concentration correlates with prostate cancer progression (60, 61), which may be 
predicted to inhibit SIRT activity and activate the AR (45). Sirtuins are located in diverse 
subcellular locations and it will be of interest to determine whether receptors in non-nuclear 
compartments are regulated by Sirtuins.  
 
Conclusion  
Nuclear receptors serve as substrates for Sirtuins and play a role in glucose metabolism, 
cell growth and DNA-repair. Evidence suggests sirtuins regulate nuclear receptors and nuclear 
receptor coactivators to coordinate diverse physiological functions.  Histones are modified by at 
least eight distinct types of enzyme. Post-translational modification of histones by specific 
enzymes determines their subsequent types of enzymatic modification. Acetylation of lysine 
residues provides docking sites for other enzymes which coordinate sequential enzymatic 
reactions. Distinct modifications of lysine residues are mutually exclusive. It has been proposed 
that post-translational modification of histones imparts specific genetic output and signaling 
specificity. Thus, post-translational modification of lysines within histone tails results in specific 
types of signaling. Nuclear receptors undergo acetylation, phosphorylation, sumoylation and 
methylation. It is likely that these post-translational modifications are part of a similar 
coordinated signaling cascade that occurs within the receptor. The mechanisms by which post-
translational modification within nuclear receptors contributes to the specificity of hormone 
signaling has broad implications for health and disease, in particular hormone-responsive 
cancers.   
 
REFERENCES  
1. Kouzarides, T. Chromatin modifications and their function. Cell, 128: 693-705, 2007.  
2. Spelsberg, T. C., Steggles, A. W., and O'Malley, B. W. Progesterone-binding 
components of chick oviduct. Chromatin acceptor sites. J. Biol. Chem., 246: 4188-4197, 
1971.  
3. Murray, M. B. and Towle, H. C. Identification of nuclear factors that enhance binding of 
the thyroid hormone receptor to a thyroid hormone response element. Mol Endocrinol, 3: 
1434-1442, 1989.  
4. Ma, J. and Ptashne, M. Converting a eukaryotic transcriptional inhibitor into an activator. 
Cell, 55, 1988.  
5. Dynlacht, B. D., Hoey, T., and Tjian, R. Isolation of coactivators associated with the 
TATA-binding protein that mediate transcriptional activation. Cell, 66: 563576, 1991.  
6. Luo, R. X., Postigo, A. A., and Dean, D. C. Rb interacts with histone deacetylase to 
repress transcription. Cell, 92: 463-473, 1998.  
7. Tasset, D., Tora, L., Fromental, C., Scheer, E., and Chambon, P. Distinct classes of 
transcriptional activating domains function by different mechanisms. Cell, 62: 1177-
1187, 1990.  
8. Vegeto, E., Allan, G.F., Schrader, W.T., Tsai, M.J., McDonnell, D.P., O'Malley, B.W., 
The mechanism of RU486 antagonism is dependent on the conformation of the 
carboxyterminal tail of the human progesterone receptor. Cell, 69: 703-713, 1992.  
9. Allan, G. F., Leng, X., Tsai, S. Y., Weigel, N. L., Edwards, D. P., Tsai, M. J., and 
O'Malley, B. W. Hormone and antihormone induce distinct conformational changes 
which are central to steroid receptor activation. J. Biol Chem, 267: 19513-19520, 1992.  
10. Yoshinaga, S. K., Peterson, C. L., Herskowitz, I., and Yamamoto, K. R. Roles of SWI1, 
SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science, 
258: 1598-1604, 1992.  
11. Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bachinger, H. P., Brennan, 
R. G., Roberts, S. G. E., Green, M. R., and Goodman, R. H. Nuclear protein CBP is a 
coactivator for the transcription factor CREB. Nature, 370: 223226, 1994.  
12. Yee, S. P. and Branton, P. E. Detection of cellular proteins associated with human 
adenovirus type 5 early region 1A polypeptides. Virology, 147: 142-153, 1985.  
13. Harlow, E., Whyte, P., Franza, B. R., Jr., and Schley, C. Association of adenovirus early-
region 1A proteins with cellular polypeptides. Mol Cell Biol, 6: 1579-1589, 1986.  
14. Kraus, W. L. and Kadonaga, J. T. p300 and estrogen receptor cooperatively activate 
transcription via differential enhancement of intiation and reinitiation. Genes and Dev., 
12: 331-342, 1998.  
15. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., and Brown, M. Cofactor dynamics and 
sufficiency in estrogen receptor-regulated transcription. Cell, 103: 843-852, 2000.  
16. Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., 
Ogryzko, V., Avantaggiati, M. L., and Pestell, R. G. p300 and p300/cAMPresponse 
element-binding protein-associated factor acetylate the androgen receptor at sites 
governing hormone-dependent transactivation. J Biol Chem, 275: 20853-20860, 2000.  
17. Lin, H. Y., Hopkins, R., Cao, H. J., Tang, H. Y., Alexander, C., Davis, F. B., and Davis, 
P. J. Acetylation of nuclear hormone receptor superfamily members: thyroid hormone 
causes acetylation of its own receptor by a mitogen-activated protein kinase-dependent 
mechanism. Steroids, 70: 444-449, 2005.  
18. Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., and Adcock, I. 
M. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables 
NF-kappaB suppression. J Exp Med, 203: 7-13, 2006.  
19. Gong, J., Zhu, J., Goodman, O. B., Pestell, R. G., Schlegel, P. N., Nanus, D. M., and 
Shen, R. Activation of p300 histone acetyltransferase activity and acetylation of the 
androgen receptor by bombesin in prostate cancer cells. Oncogene, 25: 2011-2021, 2006.  
20. Fu, M., Wang, C., Wang, J., Sakamaki, T., Di Vizio, D., Zhang, X., Albanese, C., Balk, 
S., Chang, C., Fan, S., Rosen, E., Palvimo, J. J., Janne, O. A., Muratoglu, S., 
Avantaggiati, M., and Pestell , R. G. Acetylation of the androgen receptor enhances 
coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol, 23: 8563-
8575, 2003.  
21. Fu, M., Wang, C., Wang, J., Sakamaki, T., Zhang, X., Yeung, Y.-G., Chang, C., Hopp, 
T., Fuqua, S. A. W., Jaffray, E., Hay, R. T., Palvimo, J. J., Jänne, O. A., and Pestell, R. G. 
The Androgen Receptor Acetylation governs transactivation and MEKK1-induced 
apoptosis without affecting in vitro sumoylation and transrepression function. Mol. Cell. 
Biol., 22: 3373-3388, 2002.  
22. Fu, M., Rao, M., Wu, K., Wang, C., Zhang, X., Hessien, M., Yeung, Y. G., Gioeli, D., 
Weber, M. J., and Pestell, R. G. The androgen receptor acetylation site regulates cAMP 
and AKT but not ERK-induced activity. J Biol Chem, 279: 29436-29449, 2004.  
23. Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., 
Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., Fuqua, S. A., Lopez, G. N., 
Kushner, P. J., and Pestell, R. G. Direct acetylation of the estrogen receptor alpha hinge 
region by p300 regulates transactivation and hormone sensitivity. J Biol Chem, 276: 
18375-18383, 2001.  
24. Fuqua, S. A., Wiltschke, C., Zhang, Q. X., Borg, A., Castles, C. G., Friedrichs, W. E., 
Hopp, T., Hilsenbeck, S., Mohsin, S., O'Connell, P., and Allred, D. C. A hypersensitive 
estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res, 60: 4026-
4029, 2000.  
25. Chen, H., Lin, R. J., Xie, W., Wilpitz, D., and Evans, R. M. Regulation of hormone-
induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell, 
98: 675-686, 1999.  
26. Lerin, C., Rodgers, J. T., Kalume, D. E., Kim, S. H., Pandey, A., and Puigserver, P. 
GCN5 acetyltransferase complex controls glucose metabolism through transcriptional 
repression of PGC-1alpha. Cell Metab, 3: 429-438, 2006.  
27. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., 
Auborn, K. J., Goldberg, I. D., and Rosen, E. M. BRCA1 inhibition of estrogen receptor 
signaling in transfected cells. Science, 284: 1354-1356, 1999.  
28. Wang, C., Fan, S., Li, Z., Fu, M., Rao, M., Ma, Y., Lisanti, M. P., Albanese, C., 
Katzenellenbogen, B. S., Kushner, P. J., Weber, B., Rosen, E. M., and Pestell, R. G. 
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer 
Res, 65: 6557-6567, 2005.  
29. Knights, C. D., Catania, J., Giovanni, S. D., Muratoglu, S., Perez, R., Swartzbeck, A., 
Quong, A. A., Zhang, X., Beerman, T., Pestell, R. G., and Avantaggiati, M. L. Distinct 
p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J 
Cell Biol, 173: 533-544, 2006.  
30. Kim, M. Y., Woo, E. M., Chong, Y. T. E., Homenko, D. R., and Kraus, W. L. 
Acetylation of estrogen receptor a by p300 at lysines 266 and 268 enhances the 
deoxyribonucleic acid binding and transactivation activies of the receptor. Molecular 
Endocrinology, 20: 1479-1493, 2006.  
31. Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., 
Stafford, J., Kahn, C. R., Granner, D. K., Newgard, C. B., and Spiegelman, B. M. Control 
of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature, 413: 
131-138, 2001.  
32. Knutti, D. and Kralli, A. PGC-1, a versatile coactivator. Trends Endocrinol Metab, 12: 
360-365, 2001.  
33. Wallberg, A. E., Yamamura, S., Malik, S., Spiegelman, B. M., and Roeder, R. G. 
Coordination of p300-mediated chromatin remodeling and TRAP/mediator function 
through coactivator PGC-1alpha. Mol Cell, 12: 1137-1149, 2003.  
34. Puigserver, P., Adelmant, G., Wu, Z., Fan, M., Xu, J., O'Malley, B., and Spiegelman, B. 
M. Activation of PPARgamma coactivator-1 through transcription factor docking. 
Science, 286: 1368-1371, 1999.  
35. Yu, X., Guo, Z. S., Marcu, M. G., Neckers, L., Nguyen, D. M., Chen, G. A., and 
Schrump, D. S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer 
cells by depsipeptide FR901228. J Natl Cancer Inst, 94: 504-513, 2002.  
36. Kovacs, J. J., Murphy, P. J., Gaillard, S., Zhao, X., Wu, J. T., Nicchitta, C. V., Yoshida, 
M., Toft, D. O., Pratt, W. B., and Yao, T. P. HDAC6 regulates Hsp90 acetylation and 
chaperone-dependent activation of glucocorticoid receptor. Mol Cell, 18: 601-607, 2005.  
37. Mittal, R., Peak-Chew, S. Y., and McMahon, H. T. Acetylation of MEK2 and I kappa B 
kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc Natl Acad Sci U S 
A, 103: 18574-18579, 2006.  
38. Schuur, E. R., Loktev, A. V., Sharma, M., Sun, Z., Roth, R. A., and Weigel, R. J. Ligand-
dependent interaction of estrogen receptor-alpha with members of the forkhead 
transcription factor family. J Biol Chem, 276: 33554-33560, 2001.  
39. Yamamoto, H., Schoonjans, K., and Auwerx, J. Sirtuin functions in health and disease. 
Mol Endocrinol, 21: 1745-1755, 2007.  
40. Yang, T., Fu, M., Pestell, R., and Sauve, A. A. SIRT1 and endocrine signaling. Trends 
Endocrinol Metab, 17: 186-191, 2006.  
41. Bouras, T., Fu, M., Sauve, A. A., Wang, F., Quong, A. A., Perkins, N. D., Hay, R. T., Gu, 
W., and Pestell, R. G. SIRT1 deacetylation and repression of P300 involves lysine 
residues 1020/1024 within the cell-cycle regulatory domain 1. J Biol Chem, 280: 10264-
10276, 2005.  
42. Gerhart-Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S. H., Mostoslavsky, R., Alt, 
F. W., Wu, Z., and Puigserver, P. Metabolic control of muscle mitochondrial function 
and fatty acid oxidation through SIRT1/PGC-1alpha. Embo J, 26: 1913-1923, 2007.  
43. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., and Puigserver, P. 
Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. 
Nature, 434: 113-118, 2005.  
44. Nemoto, S., Fergusson, M. M., and Finkel, T. SIRT1 functionally interacts with the 
metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem, 280: 
16456-16460, 2005.  
45. Fu, M., Liu, M., Sauve, A. A., Jiao, X., Zhang, X., Wu, X., Powell, M. J., Yang, T., Gu, 
W., Avantaggiati, M. L., Pattabiraman, N., Pestell, T. G., Wang, F., Quong, A. A., Wang, 
C., and Pestell, R. G. Hormonal control of androgen receptor function through SIRT1. 
MCB, 26: 8122-8135, 2006.  
46. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De 
Oliveira, R., Leid, M., McBurney, M. W., and Guarente, L. Sirt1 promotes fat 
mobilization in white adipocytes by repressing PPAR-gamma. Nature, 429: 771776, 
2004.  
47. Whittle, J. R., Powell, M. J., Popov, V. M., Shirley, L. A., Wang, C., and Pestell, R. G. 
Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation. Trends 
Endocrinol Metab, 2007.  
48. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., 
Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B., and Sinclair, D. A. 
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 
425: 191-196, 2003.  
49. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., 
Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., 
and Auwerx, J. Resveratrol improves mitochondrial function and protects against 
metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127: 1109-1122, 2006.  
50. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. 
V., Allard, J. S., Lopez-Lluch, G., Lewis, K., Pistell, P. J., Poosala, S., Becker, K. G., 
Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K. W., Spencer, R. G., 
Lakatta, E. G., Le Couteur, D., Shaw, R. J., Navas, P., Puigserver, P., Ingram, D. K., de 
Cabo, R., and Sinclair, D. A. Resveratrol improves health and survival of mice on a high-
calorie diet. Nature, 444: 337-342, 2006.  
51. Ju, B. G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., and 
Rosenfeld, M. G. A topoisomerase IIbeta-mediated dsDNA break required for regulated 
transcription. Science, 312: 1798-1802, 2006.  
52. Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon, L., 
Liu, P., Mostoslavsky, G., Franco, S., Murphy, M. M., Mills, K. D., Patel, P., Hsu, J. T., 
Hong, A. L., Ford, E., Cheng, H. L., Kennedy, C., Nunez, N., Bronson, R., Frendewey, 
D., Auerbach, W., Valenzuela, D., Karow, M., Hottiger, M. O., Hursting, S., Barrett, J. 
C., Guarente, L., Mulligan, R., Demple, B., Yancopoulos, G. D., and Alt, F. W. Genomic 
instability and aging-like phenotype in the absence of mammalian SIRT6. Cell, 124: 315-
329, 2006.  
53. Lin, S. J., Defossez, P. A., and Guarente, L. Requirement of NAD and SIR2 for life-span 
extension by calorie restriction in Saccharomyces cerevisiae. Science, 289: 2126-2128, 
2000.  
54. Lin, S. J., Ford, E., Haigis, M., Liszt, G., and Guarente, L. Calorie restriction extends 
yeast life span by lowering the level of NADH. Genes Dev, 18: 12-16, 2004.  
55. Fulco, M., Schiltz, R. L., Iezzi, S., King, M. T., Zhao, P., Kashiwaya, Y., Hoffman, E., 
Veech, R. L., and Sartorelli, V. Sir2 regulates skeletal muscle differentiation as a 
potential sensor of the redox state. Mol Cell, 12: 51-62, 2003.  
56. Grinspoon, S., Corcoran, C., Lee, K., Burrows, B., Hubbard, J., Katznelson, L., Walsh, 
M., Guccione, A., Cannan, J., Heller, H., Basgoz, N., and Klibanski, A. Loss of lean body 
and muscle mass correlates with androgen levels in hypogonadal men with acquired 
immunodeficiency syndrome and wasting. J Clin Endocrinol Metab, 81: 4051-4058, 
1996.  
57. Grool, L. J. D. Anabolic steroids. In (ed), Endocrinology, 3rd ed.: 2362-2369, 1995.  
58. Altenberg, B. and Greulich, K. O. Genes of glycolysis are ubiquitously overexpressed in 
24 cancer classes. Genomics, 84: 1014-1020, 2004.  
59. Chowdhury, S. K., Gemin, A., and Singh, G. High activity of mitochondrial 
glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in 
prostate cancer cell lines. Biochem Biophys Res Commun, 333: 1139-1145, 2005.  
60. Baron, A., Migita, T., Tang, D., and Loda, M. Fatty acid synthase: a metabolic oncogene 
in prostate cancer? J Cell Biochem, 91: 47-53, 2004.  
61. Rossi, S., Graner, E., Febbo, P., Weinstein, L., Bhattacharya, N., Onody, T., Bubley, G., 
Balk, S., and Loda, M. Fatty acid synthase expression defines distinct molecular 
signatures in prostate cancer. Mol Cancer Res, 1: 707-715, 2003.  
 
 
Figure Legends  
Figure 1: The histone acetylatransferase (HAT) protein, p300, is capable of regulating gene 
expression through transcription factors (TFs) and nuclear receptors (NRs) binding to DNA 
specific sequences within euchromatin. This effect is governed by K1020 and K1024 acetylation 
within p300’s CRD1 domain. SIRT1, the function of which is induced by NAD
+
 produced as a 
byproduct of oxidative phosphorylation, serves as the master regulatory protein in this process.  
 
 
 
  
 
